Cited 12 times in
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장윤수 | - |
dc.contributor.author | 차윤진 | - |
dc.date.accessioned | 2020-02-26T06:43:00Z | - |
dc.date.available | 2020-02-26T06:43:00Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1738-3536 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/175262 | - |
dc.description.abstract | BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is tested by immunohistochemistry (IHC)-22C3, SP263, and SP142. The aim of this study is to evaluate the correlation among the three methods of PD-L1 IHC in non-small cell lung cancer (NSCLC) and clinical significance of PD-L1 expression in lung adenocarcinoma with an epidermal growth factor receptor (EGFR)-tyrosine kinase domain mutation. METHODS: The results of 230 patients who were pathologically confirmed as having NSCLC; tested using PD-L1 IHC 22C3, SP263, and SP142 methods; and evaluated via the peptide nucleic acid clamping method to confirm EGFR mutation, were analyzed in this study. RESULTS: 164 patients underwent both the SP263 and 22C3 tests. There was a significant positive correlation between the outcomes of the two tests (Spearman correlation coefficient=0.912, p<0.001), with a derived regression equation as follows: 22C3=15.2+0.884×SP263 (R²=0.792, p<0.001). There was no relationship between the expression of PD-L1 and clinical parameters, including EGFR-tyrosine kinase inhibitor (TKI) mutation. The PD-L1 expression in patients treated with EGFR-TKI yielded a 2-month-shorter progression period than that in the PD-L1-negative group. However, this did not reach statistical significance (PD-L1<1% vs. PD-L1≥1%, 10 months vs. 8 months). CONCLUSION: The results of the 22C3 and those of SP263 methods were in good correlation with one another. Since the PD-L1 expression is not influenced by the EGFR mutation, it is necessary to perform a PD-L1 test to set the treatment direction in the patients with EGFR-mutant NSCLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한결핵 및 호흡기학회 | - |
dc.relation.isPartOf | TUBERCULOSIS AND RESPIRATORY DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Taehee Kim | - |
dc.contributor.googleauthor | Yoon Jin Cha | - |
dc.contributor.googleauthor | Yoon Soo Chang | - |
dc.identifier.doi | 10.4046/trd.2019.0026 | - |
dc.contributor.localId | A03456 | - |
dc.contributor.localId | A04001 | - |
dc.relation.journalcode | J02761 | - |
dc.identifier.eissn | 2005-6184 | - |
dc.identifier.pmid | 31905432 | - |
dc.subject.keyword | Companion Diagnotics | - |
dc.subject.keyword | EGFR | - |
dc.subject.keyword | Non-Small Cell Lung Cancer | - |
dc.subject.keyword | PD-L1 | - |
dc.contributor.alternativeName | Chang, Yoon Soo | - |
dc.contributor.affiliatedAuthor | 장윤수 | - |
dc.contributor.affiliatedAuthor | 차윤진 | - |
dc.citation.volume | 83 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 51 | - |
dc.citation.endPage | 60 | - |
dc.identifier.bibliographicCitation | TUBERCULOSIS AND RESPIRATORY DISEASES, Vol.83(1) : 51-60, 2020 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.